Professional Documents
Culture Documents
Ivabradine Placebo
n=2052 n=2098
-Blockers, % 87 88
At least half target dose 55 56
At target dose 26 26
ACE inhibitors/ARBs, % 90 90
Aldosterone antagonists, % 63 61
Hazard ratio=0.76
Patients with primary composite end point (%)
P<0.0001
40
Placebo
30
Ivabradine
20
10
0
0 6 12 18 24 30
Time (months)
Hazard ratio=0.83
30
P=0.0166
Patients with cardiovascular death (%)
Placebo
20
10
Ivabradine
0
0 6 12 18 24 30
Time (months)
Hazard ratio=0.70
Placebo
30
P<0.0001
Patients with cardiovascular death (%)
20
Ivabradine
10
0 6 12 18 24 30
Time (months)
75 bpm
30 70 to <75 bpm
65 to <70 bpm
60 to <65 bpm
20 <60 bpm
10
0
0 Day 28 6 12 18 24
Time (months)
40
0 bpm
30 -10 to <0 bpm
< -10 bpm
20
10
0
0 Day 28 6 12 18 24
Time (months)